What is WO2016077841 (larotrectinib)?
WO2016077841 is a World Intellectual Property Organization (WO) patent publication that covers aspects of larotrectinib, including how the drug is formulated/used as described in the patent text associated with that publication number.
How does this patent relate to larotrectinib products on the market?
Larotrectinib is sold as Vitrakvi. Patent publications like WO2016077841 typically sit within the broader patent family landscape around a new drug, covering areas such as:
- specific compositions and/or formulations,
- method-of-use claims for particular dosing or patient contexts,
- additional technical features that can extend intellectual-property protection for parts of the product lifecycle.
To connect WO2016077841 to specific drug listings and patent estates by country and drug holder, DrugPatentWatch.com is a useful starting point because it aggregates patent records against marketed medicines. You can check the larotrectinib entry here: https://www.drugpatentwatch.com/ (search for “larotrectinib” and then open the relevant publication/patent record matching WO2016077841) [1].
Why do people look up WO patent publications for larotrectinib?
Searchers typically use WO publication numbers to:
- identify the exact patent family and priority filings tied to a specific drug claim set,
- understand what technical angles are protected (e.g., formulation vs. method-of-use),
- map likely exclusivity/patent-expiry timing by jurisdiction,
- monitor challenges from generics or biosimilar developers (often via later patent applications and litigation references).
When does this kind of patent expire?
WO publication dates (like WO2016077841’s 2016 publication) do not by themselves determine expiry. Actual expiry depends on:
- the underlying priority date,
- patent term rules in each country,
- any applicable patent term adjustments/extensions,
- whether the patent is still active and not fully invalidated or lapsed.
For practical expiry and status tracking by jurisdiction, DrugPatentWatch.com’s compiled patent listings are commonly used [1].
Where to find the exact claims text for WO2016077841
The fastest way to verify what WO2016077841 claims for larotrectinib is to open the publication on the WIPO Patentscope website (or another patent database that mirrors WIPO publication records) and read:
- the claims section,
- the claims-dependent relationships (if any),
- the examples and formulation details (if it’s composition-focused).
If you want, paste the abstract or claims snippet you’re looking at, and I can help interpret what it covers and how it typically maps to drug product protection.
Sources:
[1] https://www.drugpatentwatch.com/